News Releases
News Releases
July 26, 2021
- GC Pharma to lead development and commercialization in South Korea - Mirum seeks to expand global availability of maralixibat in rare liver diseases FOSTER CITY, Calif. & YONGIN, South Korea --(BUSINESS WIRE)--Jul. 26, 2021-- Mirum Pharmaceuticals, Inc.
Additional Formats
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 12, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jul. 12, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on July 12, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 146,400 shares of common stock to
Additional Formats
Mirum Pharmaceuticals to Present at Piper Sandler’s Virtual EASL Takeaway Day
June 24, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 24, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced that it will participate in Piper Sandler’s Virtual European Association for the Study of the Liver (EASL) Takeaway Day on Monday, June 28, 2021 , at
Additional Formats
June 23, 2021
- Data from five years of treatment with maralixibat reinforces safety and tolerability in patients with Alagille syndrome. - Intrahepatic cholestasis of pregnancy patient-reported data demonstrates significant burden of disease and underscores urgent need for new treatment options.
Additional Formats
June 16, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 16, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today announced its participation in The International Liver Congress™ taking place virtually June 23-26, 2021 . The company will be presenting an integrated safety
Additional Formats
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 191,400 shares of common stock to
Additional Formats
June 7, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--Jun. 7, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart , M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco , as an independent director to its
Additional Formats
June 3, 2021
- Maralixibat-treated patients achieving serum bile acid control have improved five-year native liver survival; nominated for prestigious Alex Mowat Prize for best oral presentation in hepatology. - Safety data from more than five years of maralixibat treatment across three Phase 2 ALGS studies
Additional Formats
May 26, 2021
- Integrated safety analysis on gastrointestinal tolerability of maralixibat in patients with Alagille syndrome presented in poster session. - Five-year analysis demonstrating improvements in transplant-free survival for patients with PFIC2 featured in oral presentation; abstract nominated for the
Additional Formats
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 10, 2021
FOSTER CITY, Calif. --(BUSINESS WIRE)--May 10, 2021-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on May 10, 2021 , the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 87,500 shares of common stock to 9
Additional Formats
